Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

Treatment of chronic kidney disease in children

소아의 만성신장질환의 치료

  • Lee, Joo Hoon (Department of Pediatrics, University of Ulsan, College of Medicine, Asan Medical Center)
  • 이주훈 (울산대학교 의과대학 서울아산병원 소아과학교실)
  • Received : 2009.05.25
  • Accepted : 2009.09.11
  • Published : 2009.10.15
Download PDF
⟨ Previous Next ⟩

Abstract

The treatment of pediatric patients with chronic renal disease comprises management of nutritional imbalance, fluid, electrolyte, and acid-base disturbances, mineral bone disease, anemia, hypertension, and growth retardation. The treatment also includes administration of appropriate renal replacement therapy, if required. Adequate dietary intake of carbohydrates, fats, and proteins and caloric intake must be encouraged in such patients to ensure proper growth and development. In addition, fluid, electrolyte, and acid-base status must be regularly monitored and should be well maintained. Serum calcium, phosphorus, and parathyroid hormone levels must be maintained at their target range, which are determined on the basis of the glomerular filtration rate, to avoid the development of mineral bone disease. This can be achieved by using phosphorus binders and vitamin D analogues. An erythropoiesis-stimulating agent must be administered along with iron supplementation to maintain the hemoglobin level of the patients between 11-12 g/dL. Hypertension must be controlled with adequate water and sodium balance and appropriate antihypertensive agents. Administration of recombinant human growth hormone is recommended to improve the final adult heights.

만성 신질환 환아들의 치료는 신대체 요법과 더불어 적절한 식이 요법, 수분, 전해질 및 산-염기의 관리, 신장 골형성 장애의 예방 및 치료, 빈혈과 고혈압, 성장 지연의 치료 등으로 이루어진다. 식이 요법은 환아들의 성장이 충분히 이루어질 수 있도록 탄수화물, 지방, 단백질 및 열량의 공급이 적절하게 이루어져야 한다. 수분, 전해질 및 산-염기의 상태를 확인하고 적절하게 관리해야 한다. 혈청 칼슘, 인, 부갑상선 호르몬 농도가 사구체 여과율에 따른 적절한 목표치 안에서 유지될 수 있도록 인 결합 제제와 비타민 D 제제를 투여하여 신장 골형성 장애를 예방하여야 한다. 적혈구 생산 촉진제와 철분 제제를 투여하여 혈색소 값을 11-12 g/dl로 유지하여야 한다. 수분 및 염분의 균형과 적절한 항고혈압제의 투여로 고혈압을 조절해야 한다. 사람 재조합 성장 호르몬을 투여하여 최종 성인 키를 호전시키도록 한다.

Keywords

References

  1. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39:S1-266 https://doi.org/10.1016/S0272-6386(02)70081-4
  2. National Kidney Foundation. KDOQI Clinical Practice Guideline for Nutrition in Children with CKD: 2008 update. Executive summary. Am J Kidney Dis 2009;53:S11-104
  3. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease. Am J Kidney Dis 2005;46:S1-121
  4. Coen G, Mazzaferro S, Ballanti P, Sardella D, Chicca S, Manni M, et al. Renal bone disease in 76 patients with varying degrees of predialysis chronic renal failure: a cross-sectional study. Nephrol Dial Transplant 1996;11:813-9 https://doi.org/10.1093/oxfordjournals.ndt.a027404
  5. McSherry E, Morris RC, Jr. Attainment and maintenance of normal stature with alkali therapy in infants and children with classic renal tubular acidosis. J Clin Invest 1978;61:509-27 https://doi.org/10.1172/JCI108962
  6. Secker D. Achieving nutritional goals for children on dialysis. In: Warady BA, Schaefer FS, Fine RN, Alexander SR, editors. Pediatric dialysis. 1st ed. Boston: Kluwer Academic Publishers, 2004:221-42
  7. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42:S1-201
  8. Evenepoel P, Selgas R, Caputo F, Foggensteiner L, Heaf JG, Ortiz A, et al. Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis. Nephrol Dial Transplant 2009;24:278-85 https://doi.org/10.1093/ndt/gfn488
  9. Finn WF, Joy MS, Hladik G. Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis. Clin Nephrol 2004;62:193-201 https://doi.org/10.5414/CNP62193
  10. Goldsmith DR, Scott LJ, Cvetkovic RS, Plosker GL. Sevelamer hydrochloride: a review of its use for hyperphosphataemia in patients with end-stage renal disease on haemodialysis. Drugs 2008;68:85-104 https://doi.org/10.2165/00003495-200868010-00006
  11. Mahan JD, Patel HP. Recent advances in pediatric dialysis: a review of selected articles. Pediatr Nephrol 2008;23:1737-47 https://doi.org/10.1007/s00467-008-0825-y
  12. Seeherunvong W, Nwobi O, Abitbol CL, Chandar J, Strauss J, Zilleruelo G. Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients. Pediatr Nephrol 2006;21:1434-9 https://doi.org/10.1007/s00467-006-0204-5
  13. Drueke TB, Ritz E. Treatment of secondary hyperparathyroidism in CKD patients with cinacalcet and/or vitamin D derivatives. Clin J Am Soc Nephrol 2009;4:234-41 https://doi.org/10.2215/CJN.04520908
  14. Narayan R, Perkins RM, Berbano EP, Yuan CM, Neff RT, Sawyers ES, et al. Parathyroidectomy versus cinacalcet hydrochloride-based medical therapy in the management of hyperparathyroidism in ESRD: a cost utility analysis. Am J Kidney Dis 2007;49:801-13 https://doi.org/10.1053/j.ajkd.2007.03.009
  15. Yorgin PD, Al-Uzri A. Management of renal anemia. In: Warady BA, Schaefer FS, Fine RN, Alexander SR, editors. Pediatric dialysis. Boston: Kluwer academic publishers, 2004
  16. Rastogi A, Macdoougall IC, Nissenson AR. Anemia in PD patients. In: Khanna R, Krediet RT, editors. Nolph and Gokal's textbook of peritoneal dialysis. 3rd ed. Missouri: Springer Science, 2009:713-36
  17. Macdougall IC, Roberts DE, Coles GA, Williams JD. Clinical pharmacokinetics of epoetin (recombinant human erythropoietin). Clin Pharmacokinet 1991;20:99-113 https://doi.org/10.2165/00003088-199120020-00002
  18. National Kidney Foundation. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007;50:471-530 https://doi.org/10.1053/j.ajkd.2007.06.008
  19. Amaral S, Hwang W, Fivush B, Neu A, Frankenfield D, Furth S. Association of mortality and hospitalization with achievement of adult hemoglobin targets in adolescents maintained on hemodialysis. J Am Soc Nephrol 2006;17:2878-85 https://doi.org/10.1681/ASN.2005111215
  20. Samuels JA, Sorof JM. Blood pressure management in the dialysis patient. Boston: Kluwer academic publishers, 2004
  21. Bernstein D. Diseases of the peripheral vascular system. In: Kliegman RM, Behrman RE, Jenson HB, Stanton BF, editors. Nelson textbook of pediatrics. 18th ed. Philadelphia: Saunders, 2007:1988-9
  22. Sadowski RH, Falkner B. Hypertension in pediatric patients. Am J Kidney Dis 1996;27:305-15 https://doi.org/10.1016/S0272-6386(96)90351-0
  23. National Kidney Foundation. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004;43:S1-290
  24. Fine RN, Kohaut EC, Brown D, Perlman AJ. Growth after recombinant human growth hormone treatment in children with chronic renal failure: report of a multicenter randomized double-blind placebo-controlled study. Genentech Cooperative Study Group. J Pediatr 1994;124:374-82 https://doi.org/10.1016/S0022-3476(94)70358-2
  25. Vogt BA, Avner ED. Renal failure. In: Kliegman RM, Behrman RE, Jenson HB, F. SB, editors. Nelson textbook of pediatrics. 18th ed. Philadelphia: Saunders, 2007:2206-14
  26. Neu AM, Fivush BA. Immunizations for pediatric dialysis patients. Adv Ren Replace Ther 2000;7:239-46 https://doi.org/10.1053/jarr.2000.8130